



PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022

OXFORD, Ohio and Denver, Colorado – September 7, 2022 – PsyBio Therapeutics Corp. (TSXV:PSYB, OTCQB: PSYBF) (“**PsyBio**” or the “**Company**”), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announces that Evan Levine, Chief Executive Officer and Chairman, will present at the following upcoming conferences in September 2022:

National Investment Bank Association Florida Conference

Presentation Date & Time: 11:35 a.m. ET on September 8, 2022

Location: Hollywood, FL

Registration: <https://nibanet.org/attend-2>

H.C. Wainwright 24th Annual Global Investment Conference

Presentation Date & Time: On demand from 7:00 a.m. ET on September 12, 2022

Location: New York, NY and virtual

Registration: <https://hcwevents.com/annualconference/>

Force Family Office ‘Inventing the Future of Psychedelics’ Webinar

Presentation Date & Time: 12:00 p.m. ET on September 14, 2022

Location: Virtual

Registration: <https://forcefamilyoffice.com/events/healthcare/psybio-september-14/>

Mr. Levine will also be available for one-on-one meetings. To schedule a meeting with the PsyBio management team, please contact KCSA Strategic Communications by emailing PsyBio@kcsa.com.

About PsyBio Therapeutics Corp.

PsyBio is an intellectual property driven biotechnology company developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently

ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.

PsyBio makes no medical, treatment or health benefit claims about PsyBio's proposed products. The FDA or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio's performance and operations.

The TSX Venture Exchange (the "TSXV") has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

For further information:

Evan Levine, CEO

PsyBio Therapeutics Corp.

t: 513.449.9585

e: ir@psybiolife.com

Investor Enquiries:

Valter Pinto, Managing Director

KCSA Strategic Communications

t: 212.896.1254

e: valter@kcsa.com